Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

BMC Nephrology

Case Report

Xin An¹  Yi Zhao¹  Xiaoyan Xiao¹  Lin Ding¹  Yiyun Song¹  Xianhua Li¹  Xiangdong Yang¹ 

[1] Department of Nephrology, Qilu Hospital of Shandong University, No. 107 Wenhua West Road, 250000, Jinan, Shandong, PR China;

关键词: Rituximab;    Hypokalemia;    Nephrotic syndrome;   

DOI  :  10.1186/s12882-023-03079-4

 received in 2022-11-28, accepted in 2023-02-06,  发布年份 2023

来源: Springer

【 摘 要 】

Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We herein report two cases of symptomatic hypokalemia after intravenous rituximab administration in our center, to help health professionals consider the possibility of acute hypokalemia after rituximab administration, monitor potassium timely and develop an appropriate treatment plan.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 1